New combo pill aims for deep remission in blood cancer, hoping patients can stop treatment
NCT ID NCT05007873
Summary
This study is testing whether adding a pill called ASTX727 to the standard drug dasatinib works better for people newly diagnosed with a slow-growing type of blood cancer called chronic myeloid leukemia (CML). The goal is to achieve a very deep remission, where the cancer is nearly undetectable, which might allow patients to eventually stop treatment safely. About 70 participants will take the two-drug combination for up to 3 years, followed by dasatinib alone for up to 12 more years, to see how well it controls the disease and if it's safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.